Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 765063

Drug Profile

BI 765063

Alternative Names: Anti-SIRPa mAb - OSE Therapeutics; Anti-SIRPa monoclonal antibody - OSE Therapeutics; BI-765063; Effi dem; OSE 172

Latest Information Update: 08 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Effimune
  • Developer Boehringer Ingelheim; OSE Immunotherapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; SIRPA protein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer; Liver cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 08 Nov 2023 Boehringer Ingelheim terminates a phase I trial in Colorectal cancer (Combination therapy, First-line therapy, Neoadjuvant therapy) in USA (IV) due to company decision (NCT05446129)
  • 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
  • 14 Apr 2023 Updated efficacy and pharmacodynamics data from a phase I trial in Solid tumours presented at the114th Annual Meeting of the American Association for Cancer Research (AACR-2023) .
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top